Press release
Primary Open-Angle Glaucoma (POAG) Market to Reach USD 10.3 Billion by 2034
Primary Open-Angle Glaucoma
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72275
The POAG market is witnessing significant growth, fueled by rising prevalence of glaucoma in aging populations, advancements in minimally invasive glaucoma surgery (MIGS), and the adoption of long-acting drug delivery systems. Increasing integration of AI-powered screening and tele-ophthalmology is also helping improve early detection rates.
Market Overview
• Market Size (2024): USD 4.9 billion
• Forecast (2034): USD 10.3 billion
• CAGR (2025-2034): 7.6%
Key Highlights:
• Growing burden of glaucoma with rising global life expectancy.
• Increased adoption of sustained-release implants and long-acting drug delivery.
• Expanding role of MIGS and laser therapies in treatment.
• Strong demand for early screening and AI-driven diagnostic tools.
Segmentation Analysis
By Treatment Type:
• Medications
o Prostaglandin Analogs (first-line)
o Beta-Blockers
o Alpha-Agonists
o Carbonic Anhydrase Inhibitors
o Combination Drugs
• Laser Therapy
o Selective Laser Trabeculoplasty (SLT)
o Argon Laser Trabeculoplasty (ALT)
• Surgical Interventions
o Minimally Invasive Glaucoma Surgery (MIGS)
o Trabeculectomy
o Glaucoma Drainage Devices
• Sustained-Release Drug Delivery
o Implants (e.g., bimatoprost SR)
o Injectable Depot Formulations
By End Use:
• Hospitals & Specialty Eye Clinics
• Ambulatory Surgical Centers
• Retail & Online Pharmacies
Segmentation Summary:
Medications remain the backbone of POAG therapy, but the fastest-growing segments are MIGS and sustained-release implants, reducing reliance on daily eye drops.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72275/primary-open-angle-glaucoma-poag-market
Regional Analysis
North America
• Largest market (~42% share in 2024).
• High prevalence of glaucoma and strong adoption of MIGS and implants.
• FDA approvals driving innovation in sustained-release therapies.
Europe
• ~30% share.
• Germany, UK, and France leading adoption of advanced glaucoma surgery.
• Increasing government initiatives for early screening programs.
Asia-Pacific
• Fastest-growing region, CAGR ~8.8%.
• Large patient pool, particularly in China, India, and Japan.
• Rising demand for affordable drugs and gradual uptake of surgical innovations.
Latin America
• Brazil and Mexico expanding glaucoma care infrastructure.
Middle East & Africa
• GCC countries advancing in MIGS adoption.
• Limited awareness and late diagnosis in most African countries.
Regional Summary:
North America and Europe lead in innovation and adoption, while Asia-Pacific shows the fastest growth potential, driven by its aging population and increasing healthcare investment.
Market Dynamics
Key Growth Drivers:
• Rising prevalence of aging populations and diabetes, both risk factors for POAG.
• Growing adoption of sustained-release and long-acting therapies.
• Expanding use of AI-powered diagnostics and tele-ophthalmology.
• Increasing awareness campaigns for glaucoma screening.
Key Challenges:
• Late diagnosis leading to irreversible vision loss.
• Poor patient compliance with daily eye drop regimens.
• High costs of MIGS and implants in emerging markets.
• Limited specialist availability in rural areas.
Latest Trends:
• Expansion of minimally invasive glaucoma surgery (MIGS).
• Development of gene therapy and neuroprotective drugs for optic nerve preservation.
• Integration of home-based IOP monitoring devices.
• Use of AI-based imaging (OCT, fundus cameras) for early detection.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72275
Competitor Analysis
Major Players in the Market:
• Novartis AG (Alcon - glaucoma portfolio)
• AbbVie Inc. (Allergan - Lumigan, Combigan)
• Santen Pharmaceutical Co., Ltd.
• Bausch + Lomb
• Johnson & Johnson Vision (MIGS devices)
• Iridex Corporation (laser systems)
• Glaukos Corporation (iStent, MIGS leader)
• Aerie Pharmaceuticals (now part of Alcon)
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
Competitive Summary:
AbbVie and Novartis dominate the drug segment, while Glaukos and J&J Vision lead in MIGS devices. Bausch, Santen, and Alcon provide strong glaucoma drug portfolios, while biotech innovators are investing in neuroprotection and sustained-release therapies.
Conclusion
The Primary Open-Angle Glaucoma (POAG) Market, valued at USD 4.9 billion in 2024, is projected to reach USD 10.3 billion by 2034, growing at a CAGR of 7.6%.
Key Takeaways:
• Medications dominate today, but MIGS and long-acting implants are reshaping care.
• North America and Europe lead adoption, while Asia-Pacific grows fastest.
• AI diagnostics, sustained-release drug delivery, and gene therapy represent the future of POAG care.
• Improved compliance solutions and early screening programs will help reduce the global burden of glaucoma-related blindness.
Over the next decade, POAG management will evolve from short-term pressure control to integrated, long-acting, and potentially neuroprotective approaches, offering better long-term outcomes for millions of patients worldwide.
This report is also available in the following languages : Japanese (原発開放隅角緑内障(POAG)市場), Korean (원발성 개방각 녹내장(POAG) 시장), Chinese (原发性开角型青光眼(POAG)市场), French (Marché du glaucome primitif à angle ouvert (GPAO)), German (Markt für primäres Offenwinkelglaukom (POAG)), and Italian (Mercato del glaucoma primario ad angolo aperto (POAG)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72275/primary-open-angle-glaucoma-poag-market#request-a-sample
Our More Reports:
Neuronal Ceroid Lipofuscinosis Market
https://exactitudeconsultancy.com/reports/72866/neuronal-ceroid-lipofuscinosis-market
Meibomian Gland Dysfunction Market
https://exactitudeconsultancy.com/reports/72867/meibomian-gland-dysfunction-market
Cholangiosarcoma Market
https://exactitudeconsultancy.com/reports/72868/cholangiosarcoma-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Open-Angle Glaucoma (POAG) Market to Reach USD 10.3 Billion by 2034 here
News-ID: 4194188 • Views: …
More Releases from Exactitude Consultancy
Gene Therapy in Ophthalmology Market Set to Surge at 14.8% CAGR, Reaching USD 6. …
Introduction
Gene therapy is revolutionizing ophthalmology by offering the potential to treat and even cure previously untreatable genetic eye diseases. By targeting the underlying genetic defects responsible for conditions such as retinitis pigmentosa, Leber congenital amaurosis (LCA), X-linked retinitis pigmentosa (XLRP), and Stargardt disease, gene therapy is reshaping the future of vision care.
Unlike traditional therapies that only manage symptoms, gene therapies aim to restore or preserve vision by repairing defective genes…
Panuveitis Market to Reach USD 2.9 Billion by 2034
Panuveitis is a severe form of uveitis in which all layers of the uvea (iris, ciliary body, and choroid) are inflamed. It often results in blurred vision, eye pain, redness, light sensitivity, and floaters. The condition can be triggered by autoimmune diseases, infections, or idiopathic causes, and if untreated, can cause irreversible vision loss, glaucoma, cataracts, and retinal complications.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72271
The increasing prevalence…
Tonometers Market Projected to Grow at 7.3% CAGR, Reaching USD 730 Million by 20 …
Introduction
Tonometers are essential ophthalmic diagnostic devices used to measure intraocular pressure (IOP), a key risk factor for glaucoma. Early detection of elevated IOP is critical, as glaucoma is one of the leading causes of irreversible blindness worldwide. Regular screening through tonometry allows ophthalmologists to diagnose and manage the disease before significant vision loss occurs.
The tonometers market is evolving with the introduction of non-contact (air-puff) devices, handheld portable solutions, digital…
Ophthalmoscopes Market Poised to Grow at 7.2% CAGR, Reaching USD 640 Million by …
Introduction
Ophthalmoscopes are essential diagnostic instruments used by ophthalmologists and optometrists to examine the interior of the eye, particularly the retina, optic nerve, and blood vessels. These devices play a critical role in detecting and monitoring conditions such as glaucoma, diabetic retinopathy, macular degeneration, hypertension-related changes, and other retinal disorders.
The global demand for ophthalmoscopes is expanding due to the rising prevalence of eye diseases, aging populations, and growing emphasis on early…
More Releases for POAG
Primary Open Angle Glaucoma Clinical Trial Pipeline: Emerging Therapies Shaping …
The treatment landscape for Primary Open Angle Glaucoma (POAG), a leading cause of blindness worldwide, is undergoing significant transformation, driven by cutting-edge therapies from top pharmaceutical and biotechnology companies. Key players in the field, like Santen Pharmaceutical Co., Ltd., PH PHARMA., Whitecap Biosciences, and Ocular Therapeutix, are focusing on developing novel therapeutics that target multiple mechanisms underlying POAG, including intraocular pressure (IOP) reduction, optic nerve protection, and neuroprotection. These emerging…
Primary Open Angle Glaucoma Therapeutics Market Size in 7MM is expected to grow …
DelveInsight "Primary Open Angle Glaucoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Primary Open Angle Glaucoma, historical and forecasted epidemiology as well as the Primary Open Angle Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Primary Open Angle Glaucoma Market Share @ Primary Open Angle Glaucoma Market Outlook-…
Glaucoma Therapeutics Market 2023 Size, Share, Current Trends, Growth Analysis a …
The Glaucoma Therapeutics Market was valued at US$ 6.24 billion in 2023 and is expected to reach US$ 8.02 billion by 2031; it is estimated to record a CAGR of 3.2% during 2023-2031.
Key factors driving the market growth are the growing prevalence of glaucoma, rising awareness and early diagnosis of the disease, and increasing product launches are expected to drive the market growth. However, compliance issues with medication regimens and…
Primary Open Angle Glaucoma (POAG) Pipeline Analysis (2023) Covering Clinical Tr …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 8+ pipeline drugs in the Primary Open Angle Glaucoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Primary Open Angle Glaucoma…
Primary Open Angle Glaucoma (POGA) Market to Expand at an Immense Growth Rate Du …
DelveInsight's "Primary Open Angle Glaucoma (POGA) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Open Angle Glaucoma Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Primary Open Angle Glaucoma market report covers emerging drugs, treatment practices, market share of the individual…
Eye Care Surgical Market: Global Industry Trends, Market Size, Competitive Analy …
Orion Market Research (OMR) recently published a market research report on Global Eye Care Surgical Market. According to OMR analysis, the global Eye care Surgical Market is expected to grow significantly during the forecast period 2018-2023 due to increasing prevalence of ophthalmic diseases. Additionally, the global eye-care surgical market is segmented on the basis of type, end-user and regional outlook.
The report provides detailed & insightful chapters which include market…
